{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:30:59Z","timestamp":1761489059106},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/mpa.0b013e31826d3a17","type":"journal-article","created":{"date-parts":[[2012,12,29]],"date-time":"2012-12-29T00:27:42Z","timestamp":1356740862000},"page":"397-404","source":"Crossref","is-referenced-by-count":18,"title":["Systemic Treatment in Unresectable Metastatic Well-Differentiated Carcinoid Tumors"],"prefix":"10.1097","volume":"42","author":[{"given":"Jonathan R.","family":"Strosberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al B.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Malin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dasha","family":"Cherepanov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210212","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/17.5.303","article-title":"The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept","volume":"17","author":"Pearse","year":"1969","journal-title":"J Histochem Cytochem"},{"key":"R2-3-20210212","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.1987.5.10.1502","article-title":"Karnofsky memorial lecture: an odyssey in the land of small tumors","volume":"5","author":"Moertel","year":"1987","journal-title":"J Clin Oncol"},{"key":"R3-3-20210212","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R4-3-20210212","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","article-title":"Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival","volume":"19","author":"Halfdanarson","year":"2008","journal-title":"Ann Oncol"},{"key":"R5-3-20210212","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","volume":"340","author":"Kulke","year":"1999","journal-title":"N Engl J Med"},{"key":"R6-3-20210212","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(63)90951-6","article-title":"The classification of carcinoid tumours","volume":"1","author":"Williams","year":"1963","journal-title":"Lancet"},{"key":"R7-3-20210212","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","article-title":"The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems","volume":"39","author":"Klimstra","year":"2010","journal-title":"Pancreas"},{"key":"R9-3-20210212","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mdq290","article-title":"Gastrointestinal neuroendocrine tumors","volume":"21","author":"\u00d6berg","year":"2010","journal-title":"Ann Oncol"},{"key":"R10-3-20210212","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MPA.0b013e3181ebaffd","article-title":"NANETS consensus guidelines for the diagnosis of neuroendocrine tumor","volume":"39","author":"Vinik","year":"2010","journal-title":"Pancreas"},{"key":"R11-3-20210212","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J Clin Oncol"},{"key":"R12-3-20210212","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N Engl J Med"},{"key":"R13-3-20210212","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q","article-title":"Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors","volume":"72","author":"Saltz","year":"1993","journal-title":"Cancer"},{"key":"R14-3-20210212","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1023\/A:1008205415035","article-title":"High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects","volume":"8","author":"Eriksson","year":"1997","journal-title":"Ann Oncol"},{"key":"R15-3-20210212","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1365-2036.2000.00738.x","article-title":"Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR","volume":"14","author":"Tomassetti","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R16-3-20210212","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"R17-3-20210212","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJM198307213090301","article-title":"Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome","volume":"309","author":"Oberg","year":"1983","journal-title":"N Engl J Med"},{"key":"R18-3-20210212","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0140-6736(86)91435-2","article-title":"Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon","volume":"2","author":"Eriksson","year":"1986","journal-title":"Lancet"},{"key":"R19-3-20210212","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","article-title":"Long-term management of the carcinoid syndrome: treatment with octreotide alone and in combination with alpha-interferon","volume":"32","author":"Janson","year":"1993","journal-title":"Acta Oncol"},{"key":"R20-3-20210212","first-page":"1381","article-title":"Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R21-3-20210212","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"K\u00f6lby","year":"2003","journal-title":"Br J Surg"},{"key":"R22-3-20210212","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000201404","article-title":"Interferon-alpha versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours","volume":"57","author":"Faiss","year":"1996","journal-title":"Digestion"},{"key":"R23-3-20210212","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R24-3-20210212","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1200609","article-title":"DAXX\/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors","volume":"331","author":"Jiao","year":"2011","journal-title":"Science"},{"key":"R25-3-20210212","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"R26-3-20210212","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"R27-3-20210212","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"R28-3-20210212","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"R29-3-20210212","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9610(99)80107-X","article-title":"Hepatic resection for metastatic neuroendocrine carcinomas","volume":"169","author":"Que","year":"1995","journal-title":"Am J Surg"},{"key":"R30-3-20210212","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J Am Coll Surg"},{"key":"R31-3-20210212","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000080746","article-title":"Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"R32-3-20210212","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00268-002-6663-3","article-title":"Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors","volume":"26","author":"Hellman","year":"2002","journal-title":"World J Surg"},{"key":"R33-3-20210212","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/1097-0142(19930415)71:8<2624::AID-CNCR2820710830>3.0.CO;2-B","article-title":"Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: a prospective phase II study in 24 patients","volume":"71","author":"Ruszniewski","year":"1993","journal-title":"Cancer"},{"key":"R34-3-20210212","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/107327480601300110","article-title":"Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors","volume":"13","author":"Strosberg","year":"2006","journal-title":"Cancer Control"},{"key":"R35-3-20210212","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00130404-200307000-00008","article-title":"Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience","volume":"9","author":"Gupta","year":"2003","journal-title":"Cancer J"},{"key":"R36-3-20210212","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2293::AID-CNCR8>3.0.CO;2-E","article-title":"Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors","volume":"83","author":"Eriksson","year":"1998","journal-title":"Cancer"},{"key":"R37-3-20210212","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","article-title":"Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients","volume":"31","author":"Kennedy","year":"2008","journal-title":"Am J Clin Oncol"},{"key":"R38-3-20210212","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/SLA.0b013e3181728a45","article-title":"90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience","volume":"247","author":"Rhee","year":"2008","journal-title":"Ann Surg"},{"key":"R39-3-20210212","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol"},{"key":"R40-3-20210212","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS treatment guideline: well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"Kulke","year":"2010","journal-title":"Pancreas"},{"key":"R41-3-20210212","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"key":"R42-3-20210212","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/curroncol13020006","article-title":"Guidelines for the diagnosis and management of carcinoid tumours. Part 1: the gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group","volume":"13","author":"Maroun","year":"2006","journal-title":"Curr Oncol"},{"key":"R43-3-20210212","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/MPA.0b013e3181ebb56f","article-title":"The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas","volume":"39","author":"Strosberg","year":"2010","journal-title":"Pancreas"},{"key":"R46-3-20210212","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199806253382607","article-title":"The reproducibility of a method to identify the overuse and underuse of medical procedures","volume":"338","author":"Shekelle","year":"1998","journal-title":"N Engl J Med"},{"key":"R47-3-20210212","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM200103013440906","article-title":"Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization","volume":"344","author":"Hemingway","year":"2001","journal-title":"N Engl J Med"},{"key":"R49-3-20210212","first-page":"199","article-title":"The appropriateness of recommendations for hysterectomy","volume":"95","author":"Broder","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R52-3-20210212","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jstrokecerebrovasdis.2004.05.002","article-title":"Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: a guideline for primary care physicians from the National Stroke Association work group in recurrent stroke prevention","volume":"13","author":"Hanley","year":"2004","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"R53-3-20210212","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.fertnstert.2007.01.023","article-title":"A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding","volume":"87","author":"Fraser","year":"2007","journal-title":"Fertil Steril"},{"key":"R54-3-20210212","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.tmrv.2004.09.005","article-title":"The cost of blood: multidisciplinary consensus conference for a standard methodology.","volume":"19","year":"2005","journal-title":"Transfus Med Rev"},{"key":"R55-3-20210212","first-page":"4127","article-title":"High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors","volume":"29","author":"Chadha","year":"2009","journal-title":"Anticancer Res"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0b013e31826d3a17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:57:12Z","timestamp":1620964632000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006676-201304000-00003"}},"subtitle":["Consensus Results From a Modified Delphi Process"],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0b013e31826d3a17","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}